SAN.PA Banco Santander S.A. : Bullish and Bearish Analyst Opinions

Sanofi is trading at 10-year valuation lows (9x EV/EBIT, 12x P/E) and holds a hidden €25bn in assets via its Opella and Regeneron stakes. The core pharma business is growing at 12%. The market is overlooking both the growth in the core business and the significant value of its equity holdings, creating a mispricing. The author explicitly labels this a "TOP PICK". Sanofi offers a compelling combination of deep value, a growing core business, and hidden assets, providing a significant margin of safety and upside potential. Drug pipeline disappointments, pricing pressure in the pharmaceutical industry, or a decline in the value of its equity stakes could hinder performance.